Company news
Scisparc Ltd. (NASDAQ:SPRC) news
Scisparc Ltd. news releases on 6ix. Latest, Oct 13, 2023: SciSparc Ltd. Announces Closing of $5.026 Million Private Placement
Press releases — page 3
SciSparc Ltd. Announces Closing of $5.026 Million Private Placement
October 12, 2023
SciSparc Ltd. Announces Pricing of $5.026 Million Private Placement
October 10, 2023
SciSparc Granted European Patent for its Core Technology
October 2, 2023
SciSparc Initiated Its Clinical Trial with SCI-210 in Pediatrics with Autism Spectrum Disorder
September 28, 2023
SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split
September 26, 2023
SciSparc Announces 1-for-26 Reverse Share Split
September 19, 2023
SciSparc Engages Investment Bank to Identify Potential Strategic Transaction Opportunities
September 11, 2023
SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome
September 6, 2023
SciSparc Ltd. Closes $1.3 Million Underwritten Public Offering
August 13, 2023
SciSparc Ltd. Announces Pricing of $1.3 Million Underwritten Public Offering
August 9, 2023
SciSparc Ltd. Announces Proposed Underwritten Public Offering of Approximately $1.3 Million
August 8, 2023
SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S.
July 31, 2023
SciSparc to Commence Its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
July 13, 2023
SciSparc Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany
June 29, 2023
SciSparc Announces IRB Approval to Conduct its Phase IIb Trial in Tourette Syndrome
June 20, 2023
SciSparc Grants an Exclusive License for the Sales of CannAmide™ on the Amazon Marketplace in Canada to SciSparc Nutraceuticals
June 6, 2023
SciSparc Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer Disease Patients with Agitation Trial
June 1, 2023
SciSparc Makes Another Step Towards Unlocking Potential Value Appoints New Strategy and Business Development VP
May 29, 2023
SciSparc Completed Treatment of Last Patient Enrolled for its Phase IIa Clinical Trial for Alzheimer's Disease and Agitation
May 1, 2023
SciSparc Receives Final Approval to Commence its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome
April 3, 2023
SciSparc completes the sale of a 49% interest in its Subsidiary that owns Wellution for $3 million
March 27, 2023
SciSparc Receives Approval to conduct its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome
March 8, 2023
SciSparc Successfully Completed Production of its Proprietary Drug Candidate SCI-110 for its Upcoming Clinical Trial On Tourette Syndrome
March 5, 2023
SciSparc Signs Agreement for the Supply of CBD-rich Cannabis Oil for its Clinical Trial on Children with Autism Spectrum Disorder
February 26, 2023
SciSparc Signs a Definitive Agreement to Sell 49% interest in its Subsidiary that Owns Wellution for $2.5 million
February 22, 2023
SciSparc Announces Corporate Restructuring plan
January 24, 2023
SciSparc Receives Approval to Conduct its Clinical Trial in Children with Autism Spectrum Disorder at the Soroka Medical Center
January 17, 2023
SciSparc Announces Additional Positive Results from the Third Part of Clearmind Medicine Inc. Pre-Clinical Study for Cocaine Addiction Treatment
January 16, 2023
SciSparc Signs Agreement to Conduct its Clinical Trial in Autism Spectrum Disorder with Soroka Medical Center
January 8, 2023
SciSparc Ltd. Announces Efficacy of Psychedelic-Based Obesity Treatment of Clearmind Medicine Inc. in Pre-Clinical Trial
January 4, 2023
SciSparc Enters Into Non-Binding Letter of Intent to Sell a 50% interest in its Subsidiary that Owns an Amazon Top Seller Brand
December 13, 2022
SciSparc Announces Positive Study Results with SCI-210, a Cannabidiol-Based Treatment for Epilepsy
December 6, 2022
SciSparc Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
November 28, 2022
SciSparc Enters Into Letter of Intent with an E-commerce Company to Establish a Joint Venture to Market and Develop a New Product Line
November 14, 2022
SciSparc Gains Competitive Edge with Additional U.S. Patent Granted
November 7, 2022
SciSparc Announced Positive Interim Results Meeting Primary Endpoints at Phase IIa Study in Alzheimer’s Disease Patients with Agitation
November 6, 2022
SciSparc: Wellution™ Successfully Launched a New Keto Gummies Apple Cider Vinegar Product and Generated $100,000 In Revenues Within 30 Days
October 27, 2022
SciSparc Completes the Acquisition of Wellution™, Top Seller of American Food Supplements and Cosmetics Brand on Amazon, for $20 million
September 29, 2022
SciSparc Enters Agreement to Acquire Wellution™, Top Seller of American Food Supplements and Cosmetics Brand on Amazon, for $20 million
September 13, 2022
SciSparc Ltd. Announces Additional Positive Results for the Cocaine Addiction Treatment of its Psychedelic-based Pharma Collaboration with Clearmind Medicine Inc.
August 23, 2022
Scisparc Announces the Full Exercise of Pre-Funded Warrants
August 18, 2022
SciSparc will Deposit $1 million in Escrow for its Intention to Enter Into an Agreement to Acquire American Food Supplements and Cosmetics Brand
August 17, 2022
SciSparc Signs a Non- Binding Letter of Intent to Acquire American Food Supplements and Cosmetics Brand in Approximately $20 Million Deal
August 14, 2022
SciSparc Issued Israeli Patent for its Core Technology for Treating Central Nervous Systems Disorders
August 11, 2022
SciSparc Announces Israeli Ministry of Health Approval to Conduct its Clinical Trial in Autism Spectrum Disorder
August 7, 2022
SciSparc Signs Clinical Trial Agreement with Yale University to Conduct its Phase IIb Trial in Tourette Syndrome
July 31, 2022
SciSparc Announces Expanding its Clinical Operations to Include a U.S. Site Towards its Phase IIb Trial with its Proprietary SCI-110 for the Treatment of Tourette Syndrome
July 7, 2022
SciSparc's JV MitoCareX Bio Launches its Advanced New Laboratory Facility
July 6, 2022
SciSparc Board of Directors to Promote Buyback Program of up to $1 Million
July 5, 2022
SciSparc Successfully Completed The Development of its Proprietary Drug Candidate SCI-110 for its Upcoming Phase IIb Study In Tourette Syndrome
June 28, 2022